We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+31.45%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$854M
AUM Growth
+$40.2M
Cap. Flow
-$21.9M
Cap. Flow %
-2.56%
Top 10 Hldgs %
56.07%
Holding
53
New
14
Increased
5
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$39.7M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$14.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$13.8M
4
COGT icon
Cogent Biosciences
COGT
+$13.6M
5
ATXS
Astria Therapeutics
ATXS
+$8.92M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$25.8M
2
VTYX
Ventyx Biosciences
VTYX
+$21.9M
3
BCYC
Bicycle Therapeutics
BCYC
+$15.2M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$15.1M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
26
Olema Pharmaceuticals
OLMA
$1.09B
$9.17M 1.07%
3,743,875
– –
KYNB
27
Kyntra Bio
KYNB
$28.8M
$8.41M 0.99%
+21,000
New +$8.04M
CERE
28
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$8.2M 0.96%
+260,000
New +$7.34M
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$7.84M 0.92%
+1,250,000
New +$4.75M
ANAB icon
30
AnaptysBio
ANAB
$1.62B
$7.75M 0.91%
+250,000
New +$7.06M
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.84M 0.8%
+180,000
New +$6.19M
VERA icon
32
Vera Therapeutics
VERA
$2.55B
$5.51M 0.65%
+285,000
New +$5.16M
RXDX
33
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5.5M 0.64%
+50,000
New +$3.24M
RAPT
34
DELISTED
RAPT Therapeutics
RAPT
$3.96M 0.46%
+25,000
New +$4M
MOR
35
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.22M 0.38%
+900,000
New +$4.02M
VIGL
36
DELISTED
Vigil Neuroscience
VIGL
$2.35M 0.28%
188,390
-17,205
-8% -$211K
SPRB
37
Spruce Biosciences
SPRB
$120M
$1.1M 0.13%
13,333
– –
TYRA icon
38
Tyra Biosciences
TYRA
$1.9B
$843K 0.1%
110,856
-16,460
-13% -$116K
LIAN
39
DELISTED
LianBio American Depositary Shares
LIAN
$459K 0.05%
280,000
-27,908
-9% -$43.5K
NUVB.WS
40
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$9.63K ﹤0.01%
66,666
– –
ALT icon
41
Altimmune
ALT
$570M
– –
-750,000
Closed -$9.58M
ASND icon
42
Ascendis Pharma A/S
ASND
$16.7B
– –
-250,000
Closed -$25.8M
CMPS
43
Compass Pathways
CMPS
$1.53B
– –
-510,000
Closed -$5.47M
CNTA
44
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-399,801
Closed -$1.61M
IPSC icon
45
Century Therapeutics
IPSC
$379M
– –
-460,075
Closed -$4.55M
KZR
46
DELISTED
Kezar Life Sciences
KZR
– –
-95,000
Closed -$8.18M
PYXS icon
47
Pyxis Oncology
PYXS
$185M
– –
-220,434
Closed -$434K
TIL icon
48
Instil Bio
TIL
$48.3M
– –
-16,594
Closed -$1.61M
TRML
49
DELISTED
Tourmaline Bio
TRML
– –
-19,791
Closed -$521K
NGM
50
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-850,000
Closed -$11.1M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2022 Portfolio in Review

As of Q4 2022, Logos Global Management held 53 positions worth $854M, up 4.9% from $813M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Logos Global Management's Q4 2022 filing shows 14 new, 5 increased, 13 reduced and 13 closed positions. Its largest new stake was Immunovant: 3,150,000 shares worth $55.9M. The largest sale was Ascendis Pharma A/S, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Logos Global Management's largest Q4 2022 buy was Immunovant: 3,150,000 shares worth $55.9M.
  • Logos Global Management added most to Xenon Pharmaceuticals in Q4 2022, an estimated $14.6M increase.
  • Logos Global Management's biggest Q4 2022 reduction was Ventyx Biosciences, cutting an estimated $21.9M.
  • Logos Global Management fully exited Ascendis Pharma A/S in Q4 2022, selling an estimated $25.8M.
  • Logos Global Management's ten largest holdings make up 56% of its $854M portfolio in Q4 2022.
  • Logos Global Management opened 14 new positions and closed 13 in Q4 2022.
  • Logos Global Management's portfolio value rose 4.9% quarter-over-quarter to $854M.

Based on Logos Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.